Attack Severity in Neuromyelitis Optica Spectrum Disorder With Inebilizumab
Presenting at CMSC 2022, researchers evaluated the relationship between attack severity with serum (s) GFAP and sNfL, and the effect of inebilizumab on attack severity and serum biomarkers.